RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On January 6, 2017, RespireRx Pharmaceuticals Inc. (the Company)
announced that the Companys President and Chief Executive
Officer, James S. Manuso, Ph.D., will be presenting at The
Biotech ShowcaseTM 2017 at the Hilton San Francisco
Union Square Hotel, San Francisco, California. Dr. Manuso is
scheduled to present at 2:30 p.m. Pacific Standard Time on
Monday, January 9, 2017.
The slide presentation that the Company will be using at the
conference is attached as Exhibit 99.1 and is being furnished and
not filed to Item 7.01 of Form 8-K. The presentation will be
available by live webcast that can be accessed by clicking on the
investors tab on the Companys web-site (www.respirerx.com),
clicking on the investors tab and following the links and
instructions or by going to:
https://event.webcasts.com/starthere.jsp?ei=1130905
The press release announcing the Companys participation in the
conference is attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this
report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by
reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea. RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Recent Trading Information
RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) closed its last trading session up +0.35 at 3.25 with 2,250 shares trading hands.
